Research Data Leeds Repository
![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Data Associated with paper titled: Peptide:glycosaminoglycan hybrid hydrogels as an injectable intervention for spinal disc degeneration.
Citation
Miles, Danielle E. and Wilcox, Ruth and Beales, Paul A. (2016) Data Associated with paper titled: Peptide:glycosaminoglycan hybrid hydrogels as an injectable intervention for spinal disc degeneration. University of Leeds. [Dataset] https://doi.org/10.5518/47
Dataset description
Degeneration of the spinal discs is a major cause of back pain. During the degeneration process, there is a loss of glycosaminoglycans (GAGs) from the proteoglycan-rich gel in the disc’s nucleus, which adversely alters biomechanical performance. Current surgical treatments for back pain are highly invasive and have low success rates; there is an urgent need for minimally-invasive approaches that restore the physiological mechanics of the spine. Here we present an injectable peptide:GAG hydrogel that rapidly self-assembles in situ and restores the mechanics of denucleated intervertebral discs. It forms a gel with comparable mechanical properties to the native tissue within seconds to minutes depending on the peptide chosen. Unlike other biomaterials that have been proposed for this purpose, these hybrid hydrogels can be injected through a very narrow 25 G gauge needle, minimising damage to the surrounding soft tissue, and they mimic the ability of the natural tissue to draw in water by incorporating GAGs. Furthermore, the GAGs enhance the gelation kinetics and thermodynamic stability of peptide hydrogels, significantly reducing effusion of injected material from the intervertebral disc (GAG leakage of 8 [1] 3% after 24 h when peptide present, compared to 39 [1] 3% when no peptide present). In an ex vivo model, we demonstrate that the hydrogels can restore the compressive stiffness of denucleated bovine intervertebral discs. Compellingly, this novel biomaterial has the potential to transform the clinical treatment of back pain by resolving current surgical challenges, thus improving patient quality of life.
Files
Documentation
Dataset summary [5kB]  |
Dataset summary [5kB] 
Dataset summary [5kB] Data
Concept schematic of a peptide:GAG hybrid hydrogel as a minimally invasive nucleus pulposus replacement. [6MB] |
Apparent critical concentration for aggregation as determined by 1H NMR for peptide only and peptide :GAG 1 : 10 samples, 130 mM NaCl and 1.25 mM TMSP in D2O [174B] |
Band fitted FTIR amide I’ region of P11-8:GAG spectra [22kB] |
Band fitted FTIR amide I’ region of P11-8 spectra [16kB] |
Band fitted FTIR amide I’ region of P11-12:GAG spectra [16kB] |
Band fitted FTIR amide I’ region of P11-12 spectra [16kB] |
Percentage b-sheet as determined by FTIR for peptide only and peptide :GAG 1 : 10 samples in 130 mM NaCl in D2O [153B] |
TEM image showing morphology of peptide aggregates, P11-12 :GAG 1 : 10. [1MB]  |
TEM image showing morphology of peptide aggregates, P11-12 [1MB]  |
TEM image showing morphology of peptide aggregates, P11-8 :GAG 1 : 10. [912kB]  |
TEM image showing morphology of peptide aggregates, P11-8 [1MB]  |
Optical micrograph of P11-9 [2MB]  |
Optical micrograph taken through polarised lense of P11-9 [1MB]  |
Elastic and viscous components of the shear modulus at 2 Hz for peptide and peptide:GAG samples [268B] |
Comparison of percentage of added GAG leaked from a disc over a 48 h time period when injected with 1 : 10 GAG only and 1 : 10 P11-12 :GAG [145B] |
Normalised stiffness for each sample type as an average of the 6 discs tested [120B] |
Apparent critical concentration for aggregation as determined by 1HNMR for P11-12 only and P11-12:GAG 1:2, 1:5 and1:10 samples [105B] |
Band fitted FTIR amide I’ region of P11-4:GAG spectra [17kB] |
Band fitted FTIR amide I’ region of P11-4 spectra [22kB] |
Band fitted FTIR amide I’ region of P11-9:GAG spectra [18kB] |
Band fitted FTIR amide I’ region of P11-9 spectra [16kB] |
1HNMR aromatic region integral of P11-12 relative to integral of 0.125 mM TMSP reference peak as a function of increasing peptide concentration and time from sample preparation with and without the presence of GAG at a ratio of 1:5. [2kB] |
Gel rheological properties of peptide control, peptide:GAG 1:2 and peptide:GAG 1:10, for P11-4, P11-8, P11-9 and P11-12. P11-4 [1kB] |
P11-4 GAG unprocessed FTIR spectra [54kB] |
P11-4 unprocessed FTIR spectra [54kB] |
P11-8 GAG unprocessed FTIR spectra [54kB] |
P11-8 unprocessed FTIR spectra [54kB] |
P11-9 GAG unprocessed FTIR spectra [54kB] |
P11-9 unprocessed FTIR spectra [54kB] |
P11-12 GAG unprocessed FTIR spectra [54kB] |
P11-12 unprocessed FTIR spectra [54kB] |